When the study patients with PAD received ASA alone or ASA plus rivaroxaban, the platelets were able to reverse the PGE1-mediated VASP phosphorylation at S239 by ADP-induced P2Y12 signaling, expressed by a PRI higher than 50% as expected. The gene discussed is VASP; the disease is peripheral arterial disease.